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Cytokine-induced killer (CIK) cells are polyclonal T eﬀector cells generated when cultured under cytokine stimulation. CIK
cells exhibit potent, non-MHC-restricted cytolytic activities against susceptible tumor cells of both autologous and allogeneic
origins. Over the past 20 years, CIK cells have evolved from experimental observations into early clinical studies with encouraging
preliminary eﬃcacy towards susceptible autologous and allogeneic tumor cells in both therapeutic and adjuvant settings. This
paper is our attempt to summarize the available published literature related to CIK cells. Looking into the future, we anticipate
that the continuous therapeutic application of CIK cells will likely be developed along two major directions: overcoming the
challenge to organize large prospective randomized clinical trials to deﬁne the roles of CIK cells in cancer immunotherapy and
expanding its spectrum of cytotoxicity towards resistant tumor cells through experimental manipulations.
1.Background
One of the ﬁrst prototypes of cytokine-induced immune-
eﬀector cells is the Lymphokine-Activated Killer (LAK)
cells. Firstly described in the early 1980s, LAK cells are
cytotoxic eﬀector lymphocytes whose cytolytic activities are
not restricted by major histocompatibility complex (MHC)
and have the ability to kill fresh tumor cells and NK-resistant
tumor cell lines [1]. LAK cells are generated following
expansion in the presence of IL-2 for a relatively short
culture period of approximately 5 days. After culture, the
heterogeneous LAK cell population consists of CD3−Leu19+
NK cells, CD3+Leu19+ cells, and CD3+Leu19− T cells.
Leu19 was subsequently redesignated as CD56 and these
CD3+CD56+ cellsarealsotermednon-MHC-restrictedcyto-
toxicTcells.ThetwocellsubsetstheCD3+Leu19+ Tcellsand
CD3−Leu19+N Kc e l l sc o n t r i b u t et ot h ec y t o l y t i cp r o p e r t y
of LAK cells [2]. Over the years, various improvements
in the methods to culture LAK cells have been developed.
These included the addition of OKT3 at the initiation of
culture, prolongation of culture duration, and the addition
of various diﬀerent types of cytokines at the end of culture.
These improved methodologies to culture LAK cells resulted
in better expansion over the originally described method
[3]. LAK cells demonstrated potent in vitro cytotoxicity
against susceptible tumor cells and led to the regression
of established tumors in animal models [4, 5]. In clinical
studies, LAK cells had demonstrated modest eﬃcacy against
metastaticcancersuchasrenalcellcarcinomaandmelanoma
[6]. In a randomized controlled trial in the 1990s, adoptive
immunotherapy using ex vivo activated T cells showed
clinical eﬃcacy in terms of prolongation of relapse-free
survivalforpatientswithhepatocellularcarcinomafollowing
resection of the primary tumor [7].
The discovery, generation, and therapeutic use of
immune-active host eﬀector cells that can kill cancer cells
are continuously being developed. The pioneering work that
accelerated the ﬁeld of cellular immunotherapy with CIK
cells was performed in Stanford. The authors described CIK
cells as non-MHC-restricted T cells with marked ability to
proliferate and demonstrated superiority over LAK cell in
cytolytic activities against B cell lymphoma [8]. Further-
more, CIK cells exhibit potent in vivo cytolytic activities
without the need for coadministration of IL-2. CIK cells are
generated by the timed addition of IFN-γ 1000u/ml on day
1 of culture, followed 24 hours later by the addition of anti-
CD3 at 50ng/ml and IL-2 at 300IU/ml. Together with the
periodic addition of IL-2, the culture medium is regularly2 Journal of Biomedicine and Biotechnology
Table 1: Comparison of the three subsets of cells in a CIK culture. NA = not applicable, ND = not done.
Subset Name
Cytotoxicity Target class I Immunophenotype
versus versus versus Blocked Enhanced %CD8 Memory T cell subset Granzyme
AML ALL K562 content
CD3−D56+ NK cells + 0 ++++ Killing ↑ Killing ↓ NA NA ND
CD3+CD56+ NK-like T cells +++ 0 0 Killing ↓ Killing ↑ higher CD27+/−CD28−CD62L+ late T eﬀector higher
CD3+CD56− T cells + 0 0 Killing ↓ Killing ↑ lower CD27+CD28+CD62L+early T eﬀector lower
replenished throughout the culture period of 21–28 days [8].
At the end of the culture, the CD3+CD56+ cells, derived
from CD3+CD56− cells, could expand by up to 1000-fold
and gave the greatest cytotoxicity against various tumor cell
targets, including K562 and B cell lymphoma cell lines, as
compared to CD3+CD56− cells [9]. The expression of CD56
on these non-MHC-restricted eﬀector T cells was found to
be the result of IFN-γ-priming that induced the production
of IL-12 by monocytes and the upregulation of CD58 (LFA-
3), both of which were demonstrated to be crucial for
the expansion of CD56+ T cells [10]. Subsequently, this
unique subset of non-MHC-restricted CD3+CD56+ Tc e l l s
was referred to as NK-like T cells since, similar to the NK
cells,theydonotrequirepriorspeciﬁcsensitizationtoinduce
the recognition of target cells.
2. Functional,Phenotypic, andGenotypic
Characterizationof CIKCells
Following bulk culture in vitro, the eﬀector cell population
obtained is heterogeneous and comprises of a small fraction
(∼2%) of CD3−CD56+ NK cells and >90% of CD3+
cells of which ∼35% expresses CD56 while the remaining
cells are CD3+CD56− [11]. The sorted NK cell fraction
(CD3−CD56+) behaves like classical NK cells and the killing
of autologous acute myeloid leukemia (AML) target cells
mediatedbythesecellscanbeenhancedbyblockingtheHLA
class I molecules on the target cells [12]. The CD3+CD56+
subset, termed non-MHC-restricted T cells, is able to kill
both autologous and allogeneic susceptible tumor targets
such as primary AML cells of disparate HLA types [11].
However, we have earlier shown that this subset of cells
recognizes target cells through the T cell receptor (TCR)
and requires the presence of MHC molecules on the target
cells, a phenomenon similar to that observed for classical
cytotoxic T lymphocytes. Furthermore, blockade of either
TCR on the eﬀector cells or the MHC class I molecules
on the target cells abrogates the killing of target cells [12].
This discrepant observation of being not restricted by the
MHCspeciﬁcityinitscytolyticactivitiesbutwiththeeﬀector
function dependent on the presence of MHC is inconsistent
with the current T cell paradigm, which dictates that
cytotoxic eﬀector T lymphocytes recognize target peptides
in the context of self-MHC molecules. Besides our report,
similar observations had also been independently made by
others [13–15]. A hypothetical working explanation is that
T cells in an “activated” state induced by cytokines could
express elevated levels of adhesion molecules which result in
the recognition of target cells more readily and eﬃciently,
overriding the requirement for stringent matching of the
MHC molecules. While these T cells are labeled as “NK-like”,
we demonstrated that the well-characterized conventional
NK receptors, including the KIR, NKG2C/E, NKG2D, and
DNAM-1, are not involved in the recognition and killing
of AML targets [12]. The exact molecules responsible for
the recognition of AML targets await further molecular
characterization. While CIK cells have been shown to kill the
myeloma cell line U266 via NKG2D-mediated recognition of
its cognate ligands MICA and MICB on the target cells [16],
the same mechanism is unlikely to be operative for AML tar-
getsasthesetargetcellsdonotexpressMICAandMICB[17].
Investigation into the possible explanations for the better
cytolytic activities against tumor cells demonstrated for the
CD3+CD56+ cells over its CD3+CD56− counterpart revealed
that the CD3+CD56+ cells consist of a higher proportion
of CD8+ cells compared to the CD3+CD56− cell subset.
Furthermore, the CD3+CD56+ subset is a more terminally
diﬀerentiated late eﬀector T cell population bearing the
CD27+CD28− or CD27−CD28− phenotypes. In contrast,
the CD3+CD56− cells are early eﬀector T cells expressing
mainly the CD27+CD28+ and CD62L+ phenotypes. The
granzyme content is also higher in the CD3+CD56+ T cells,
consistent with the report that late eﬀector T cells possess
more potent cytotoxicity than early eﬀector T cells [12].
Table 1 summarizes the characteristics of the three subsets of
cells in the bulk CIK culture.
Our research focus is on the cellular immunotherapy of
hematological malignancies and we have observed that CIK
cells kill AML blasts eﬃciently but not acute lymphoblastic
leukemia (ALL) blasts [11]. The resistance of ALL blasts to
killing by immune eﬀector cells has also been well reported
by others [18, 19]. We therefore also studied the possible
molecular event that might explain this discrepancy. We
observed that the CD3+CD56+ fraction of CIK cells cultured
from acute leukemic marrow at diagnosis expressed high
levels of immune function genes including IFN-γ,T N F α,
CXCR3, CCR1, granzyme B, CCL3 (MIP-1α), CCL4 (MIP-
1β), CCL5 (RANTES), IL-7R, IL-12Rβ2, and caspase-1, con-
sistent with a Th1 and Tc1 polarization [20]. Upon stimula-
tion by the corresponding leukemic targets, that is, CIK cells
derived from AML patients coincubating with autologous or
allogeneic AML blasts and similarly, CIK cells derived from
ALL patients coincubating with autologous or allogeneicJournal of Biomedicine and Biotechnology 3
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Figure 1: Marrow cells obtained from newly diagnosed AML samples analyzed by side scatter versus CD45 staining show a large proportion
of leukemic blasts that are CD45dim and a much smaller fraction of normal lymphocytes that are CD45bright (a). Culture of the bulk marrow
cells comprising of majority of leukemic blasts with a small fraction of lymphocytes under CIK condition (b) is able to generate an end
product comprising of a majority of CD3+ cells with a variable CD3+CD56+ fraction (c).
ALL blasts, immune response-related genes like IFN-γ,
GM-CSF, IL-4, IL-8, cytokine receptor genes IL-2Rβ,I L -
2Rα, IL-4R, IL-12Rβ, IL-15Rα, chemokine and chemokine
receptor genes, and genes belonging to the TNF and TNF
receptor superfamily were upregulated. Many proapoptotic
genes were downregulated whilst antiapoptotic genes were
upregulated. One observation of great interest was that genes
encoding the NK receptors NKG2C, NKG2E, and CD94 were
exclusively upregulated in CIK cells stimulated with myeloid
blasts but not lymphoid blasts. In contrast, TGFβ-1 gene
transcript was upregulated in CIK stimulated with lymphoid
blasts. The diﬀerential regulation of these immune-related
genes corroborated with our observed ﬁndings of good CIK
killing against myeloid but poor killing against lymphoid
blasts [20]. However we did not detect surface expression
of NKG2C and NKG2E molecules on the CIK cells both
before and after stimulation with myeloid target cells [12].
Therefore, the molecular and cellular signiﬁcance of the
upregulation of these immune-related genes needs to be
further investigated.
3. In VitroAntitumor Activityof CIK Cells
Over the years, CIK cells have been tested for its antitumor
activity against a variety of tumor targets. It was ﬁrst
shown to be able to kill t(14;18)-positive lymphoma cell
lines but not against normal human hemopoietic precursors
[8]. Doxorubicin- and vinblastine-resistant tumor cell lines
expressing high level of Pgp (P-glycoprotein) were also
susceptibletoCIK-mediatedlysis[21].Furthermore,chronic
myeloid leukemia (CML) colony growth was reported to be
suppressed by CIK cells and after 28 days of coincubation,
the remaining colonies in culture were exclusively composed
of Philadelphia- (Ph-) negative cells [22, 23]. Previously,
we have shown that CIK cells could be generated from the
marrow or peripheral blood samples from acute leukemia
patients collected at diagnosis. Figure 1 shows the change in
the composition of cells cultured under CIK condition from
astartingcellpopulationconsistingofamajorityofleukemic
blasts with typically less than 10% T cells, to a majority
of T cells at maturity. These cells were lytic against both
autologous and allogeneic AML targets [11]. Additionally,
CIK cells could also be generated from untreated chronic
lymphocytic leukemia (CLL) patients, where cytotoxicity
against autologous CLL targets could be induced by addition
of anti-CD3 MoAb [24, 25].
Immunological manipulations aimed to potentiate the
antitumor activity of CIK cells have been explored. Hence,
dendritic cells (DC) were cultured and engineered to present
tumor antigens to CIK cells hoping that this might enhance
the recognition of tumor cells and its subsequent killing.
This was shown to be feasible for multiple myeloma (MM)
when the DC was pulsed with target-derived idiotype before
coculture with the CIK cells [26]. CIK-resistant pancreatic
carcinoma target cells also became susceptible to CIK cells
that were cocultured with DC loaded with tumor-restricted
RNA and the CA19-9 peptide [26, 27]. Furthermore, trans-
fection of IL-2 genes into CIK cells to enhance its IL-2
production potentiated its cytotoxicity against a pancreatic
cancer cell line following coculture with DC when compared
to non-IL-2-transfected CIK cells [28].
4. Mice Studies
Earlier work had shown the antitumor activity of CIK cells
in mice. Human B cell lymphoma cell lines harboring the
t(14;18) chromosomal translocation were injected into SCID
mice to evaluate the eﬃcacy of CIK cells. When allogeneic
CIK cells were injected 1 day after inoculation of tumor cells,
theSCIDmicereceivingtheCIKcellshadprolongedsurvival4 Journal of Biomedicine and Biotechnology
compared to control mice and LAK cell-treated mice, with
long-term survival of 30% and no molecular evidence of
lymphoma [9]. In SCID mice engrafted with human CML,
autologous CIK cells transfer 4 weeks after inoculation of
tumorcellsresultedineradicationofbcr-ablwhichremained
detectable in control mice [22]. This study showed that CIK
cells,whicharePhchromosome-negative,couldbeexpanded
from patients with CML and had potent in vitro and in vivo
eﬃcacy against autologous tumor cells. In the same study,
an additional series of SCID mice was not engrafted with
CML but they instead unexpectedly developed large human
Epstein-Barrvirus-associatedlymphomas.Withinthisseries,
the CIK cells-treated group developed no or small tumor as
compared to large tumor developed in the untreated group
[22]. These experimental data served as convincing early
evidence of in vivo eﬃcacy of CIK cells.
With the availability of the bioluminescence imaging
(BLI) technology [29], the in vivo functional activities of
CIK cells could be visualized in a real-time fashion in mice
inoculated with bioluminescent gene-transfected tumor cells
and treated with CIK cells for cellular immunotherapy. To
monitor tumor regression by BLI, mice were implanted
intraperitoneal with HeLa-luc (a luciferase gene-transfected
humancervicalcarcinomacellline)andsubsequentlytreated
with CIK cells. Mice treated with CIK cells had signiﬁ-
cant tumor regression or complete eradication compared
to saline-treated mice [30]. Similar tumor response was
visualized for murine lymphoma cell lines [31]. Using the
same strategy, CIK cells were transfected with the gfp/luc
genes to visualize its traﬃcking by BLI [31]. Following
injection, it was observed that luc+ CIK cells ﬁrst reached the
lungs within 30 minutes followed by a general distribution to
other sites of the body. By the 7th hour, a population of the
labeled CIK cells migrated to the tumor sites and remained
detectableatthesesitesforanadditional9dayswithresultant
tumor regression [31]. Importantly, this antitumor eﬀect of
CIK cells occurred without the need for exogenous IL-2, a
clinically relevant observation.
5.CIKCellsAcross MHCBarrier
Donor lymphocyte infusion (DLI) is used to increase the
graft-versus-tumor (GVT) eﬀect after allogeneic hematopoi-
etic cell transplant. The role of DLI in the management of
malignancies remains restricted mainly due to the limited
spectrum of activity and high risk of graft-versus-host
disease (GVHD). The ﬁnding of new cell populations for
adoptive immunotherapy with the ability to separate GVT
from GVHD would be useful. Being non-MHC-restricted
and active against autologous and allogeneic tumor cells
with comparable eﬃcacy [11], CIK cells have therefore been
exploited in studies related to both its eﬃcacy and possible
toxicity due to GVHD across MHC barrier. In an allogeneic
model where transplant with puriﬁed hemopoietic stem cell
was done across major MHC barrier from H-2b donors
into murine lymphoma-inoculated H-2d recipient mice,
transplanted mice died from persistent lymphoma [32].
However, recipient mice infused with CIK cells expanded
from donor mice had reduction of lymphoma and 50%
survived long term, with no or minimal GVHD. In contrast,
recipient mice that were treated with unmanipulated donor
splenocytes died from acute GVHD [32]. This observa-
tion suggests that expanded CIK cells mediate signiﬁcant
graft-versus-tumor eﬀect without signiﬁcant GVHD even
when transplanted across MHC barrier. The mechanism
of reduced GVHD induction was postulated to be related
to IFN-γ production [33]. In an MHC-mismatched model
when mice bearing the A20 leukemia/lymphoma B cells were
treated with allogeneic CIK cells, the donor CIK cells were
observed to inﬁltrate GVHD target tissues to a lesser extent
and for a shorter duration than unmanipulated splenocytes,
resulting in milder histological changes in the gut and liver
[34]. Instead, CIK cells were found to accumulate and
persist at tumor sites resulting in eradication of established
tumor [34]. These encouraging experimental data may be
important information for application in human allogeneic
transplantation where donor CIK cells may prove to be
superior and hopefully safer than unmanipulated DLI in the
prevention or treatment of relapse.
6. Novel Development
Exciting development that promised to broaden the appli-
cation of CIK cell was reported over recent years. Primary
ovarian carcinoma cells are resistant to CIK-mediated lysis.
However, it was demonstrated recently that the addition
of bispeciﬁc antibodies (BsAb) CD3xCA125 or CD3xHer2
(heteroconjugates of anti-CD3 with anti-CA125 or Her2,
resp.) could eﬃciently target the CD3+ CIK cells to ovarian
carcinoma bearing the speciﬁc ovarian tumor antigens and
overcome the resistance. This strategy was shown to be eﬀec-
tive against autologous primary ovarian tumor cells in vitro
and in ovarian tumor-bearing mice. The survival of mice
with ovarian carcinoma treated with CIK cells redirected by
the BsAb was prolonged compared to control mice treated
with CIK cells alone [35]. In an attempt to treat the Ewing’s
family tumors (EFTs), the low levels of cell surface Her2/neu
expression were employed to redirect ex vivo activated CIK
cells to tumor targets using the BsAb CD3xHer2/neu [36].
It was demonstrated that CD3xHer2/neu could be used to
redirect CIK cells to mediate cytotoxicity against EFTs.
Besides using BsAb, other methods of harnessing
antigen-antibodyaﬃnitytoredirectCIKcellstotargettumor
cells involved the transfection of CIK cells to express tumor-
speciﬁc receptors. CIK cells are known to be inactive against
BcellALLtargetsinvitro,butCIKcellsengineeredtoexpress
the chimeric receptor speciﬁc for the CD19 antigen could
redirect CIK cells and become cytotoxic towards CD19-
expressing B cell ALL targets [37].
Another innovative genetic modiﬁcation of CIK cells was
the transfection of CIK cells with oncolytic viruses. These are
viruses with the ability to infect only transformed (tumor)
cells. A modiﬁed double-deleted vaccinia virus (vvDD) was
able to infect CIK cells without aﬀecting its activity. CIK cells
were employed as a carrier vehicle bringing the oncolytic
virus to tumor cells through the NKG2D receptor which is
highly expressed by CIK cells to its ligands MICA and MICB
on the tumor cells. VvDD-carrying CIK cells migrated to theJournal of Biomedicine and Biotechnology 5
Table 2: Activities of CIK cells from preclinical experiments to clinical studies.
In vitro cytotoxicity Ref
Cell lines B cell lymphoma SU-DHL [8, 9]
Multiple myeloma OPM-2,U266 [16, 26]
T cell ALL CCRF-CEM-VBL (Vinblastine resistant) [21]
Erythroleukemia K562/Dox(Doxorubicin resistant) [21]
Primary tumor cells Acute myeloid leukemia [11]
Chronic myeloid leukemia [22, 23]
Chronic lymphocytic leukemia [24, 25]
Multiple myeloma [26]
Mice studies
Cell lines Human B cell lymphoma Su-DHL [8, 9]
Human cervical cancer HeLa [30]
Murine B cell lymphoma BCL1 [31, 32]
Primary tumor cells Chronic myeloid leukemia [22]
Chronic lymphocytic leukemia [24]
CIK cells administered with additional manipulation
With BsAb CIK + BSAbxCA125 or BSAbxHER2 versus ovarian primary tumor and cell lines in vitro and in
mice
[35]
CIK + CD3xHER2/neu bsAb versus Ewing’s family tumor cell lines in vitro and in mice [36]
Gene transfection IL-2 gene electroporated CIK + DC versus pancreatic tumor cell line Dan G [28]
Anti-CD19 chimeric receptor-redirected CIK versus ALL cell line REH and primary ALL cells [37]
Oncolytic virus transfected CIK versus human ovarian cell lines UCI-101 and SK-OV-3 in vitro and
in mice
[38]
Clinical studies with demonstrated tumor response
Treatment: autologous Follicular lymphoma (1 case) [41]
Hodgkin’s disease (2 cases) [42]
Renal cell carcinoma (1 case) [47]
Treatment: allogeneic Myelodysplastic syndrome (1 case), Hodgkin’s disease (1 case), Acute myeloid leukemia (1 case) [49]
Clinical studies in adjuvant setting with demonstrated reduction in relapse
Autologous Acute myelogenous and lymphoblastic leukemia [44]
Hepatocellular carcinoma (intra-arterial) [46]
tumor sites where the oncolytic viruses were then released to
speciﬁcally lyse tumor cells. This approach has been success-
fully shown to work using mouse models for human ovarian
tumor and murine breast carcinoma, resulting in reduction
of tumor burden and prolongation of survival [38].
7.ClinicalTrials
CIK cells can be generated successfully from healthy donors
as well as patients treated with chemotherapy for various
malignancies and undergoing peripheral blood progenitor
cell (PBSC) leukapheresis [39]. Feasibility of large-scale
expansion was also reported for cord blood and even from
washout of leftover mononuclear cells from cord blood unit
bags [40]. Several phase I trials to test the clinical eﬃcacy of
CIK cells on a small number of patients have been reported.
The ﬁrst clinical trial using CIK cells was reported in 1999 by
Schmidt-Wolf et al. in Germany using autologous CIK cells
electroporated with IL-2 genes for infusion into 10 patients
with metastatic renal carcinoma, colorectal cancer, and
lymphoma. One patient with follicular lymphoma showed
complete response. No major side eﬀect was observed,
except for 3 patients who developed fever that spontaneously
resolved [41]. Negrin’s group at Stanford reported giving
9 patients autologous CIK cells to treat relapsed Hodgkin
disease (HD) and non-Hodgkin lymphoma (NHL) postau-
tologous transplantation. Besides demonstrating the feasi-
bility of large-scale expansion of CIK cells and the absence6 Journal of Biomedicine and Biotechnology
of adverse reaction, this trial achieved 2 partial responses
and 2 stabilization of disease in the recipients [42]. In
another phase I/II study, autologous CIK cells were given as
anadjuvantimmunotherapypostautologoustransplantation
for 9 high risk HD and 4MM patients, again demonstrating
safety as well as the maintenance of disease response in these
high risk patients in the ﬁrst year post-transplantation [43].
In the adjuvant therapy of acute leukemia, a study from
China reported that 73.4% of the 19 patients who received
1–4 courses of autologous CIK cell infusions in combination
with consolidation chemotherapy remained in continuous
remission for a follow-up period of 4 years, compared to
27.3% in the chemotherapy-only group [44].
CIK cells have also been explored in clinical trials to
treat solid tumors by investigators in China. In one report,
patients with stage IV stomach cancer who were treated with
chemotherapy and received additional CIK cell infusions
had a higher overall short-term remission rate of 56.3% as
compared to 48% in the chemotherapy-only group [45].
In another study, patients with hepatocellular carcinoma
who achieved complete remission with transcatheter arte-
rial chemoembolization and radiofrequency ablation were
divided into two groups, where intrahepatic arterial CIK cell
infusion was given to a study group of 45 patients. Relapse
at 1.5 years occurred in 31.1% of patients in the CIK group
as compared to 85% in the control group, with the diﬀerence
mainly accounted for by the signiﬁcantly lower relapses seen
at local sites (15.56% versus 65%, resp.) [46]. The same
groupalsoreportedtheirexperiencein10patientswithrenal
cellcarcinomapostnephrectomywhoweregivenintradermal
autologous dendritic cells pulsed with autologous tumor
lysate and followed by autologous CIK cell infusions. In 4
patients with evaluable disease, one case of partial response
in terms of resolution and reduction in the size of metastatic
lung nodules was observed [47].
In the allogeneic setting, an early abstract from Stanford
in 2006 reported 10 patients with various hematological
malignancies relapsing after allogeneic transplant-received
cytoreductivetreatmentfollowedbydonorCIKcellinfusions
in escalating doses up to 1 × 108 CD3/kg. Grade I acute
GVHD occurred in 1 patient and limited chronic GVHD in
2 patients [48]. Another report from Italy studied 11 patients
in similar clinical settings and with variable doses adminis-
tered for each patient. As often occurs in such settings where
other salvage therapies are being used concurrently, it was
diﬃcult to assess the eﬃcacy. Nevertheless, 3 patients (1 each
with MDS, HD, and AML) achieved measurable response, in
terms of improvement in donor chimerism or clearance of
disease, that could be solely attributable to donor CIK cell
infusions. Similarly, GVHD rate was not higher than that
of unmanipulated DLI, with grade I and II acute GVHD
in 4 patients, 2 of whom progressed to extensive chronic
GVHD [49]. In our own experience using allogeneic donor
CIK cells to treat patients in relapse who are refractory to
chemotherapy and DLI, response attributable solely to CIK
infusions was also seen in a few patients. GVHD involving
mainly skin and liver was sometimes observed but was easily
controlled (Linn and Hui, unpublished data).
8. FutureDirections
Over the years, investigators have learnt to generate various
types of cytotoxic eﬀector cells and have used them for the
cellular immunotherapy of human cancer. CIK cells, either
in autologous or allogeneic context, have demonstrated
encouraging results both in vitro and in clinical studies
by various groups, as summarized in Table 2.A d v a n c e si n
genetic engineering technologies could further broaden the
potential clinical applications of CIK cells if the challenge
to conform these genetic engineering technologies to GMP
compliance could be overcome. However, clinical studies
with CIK cells are still in their infancy and only involved a
relatively small number of patients in most of these studies.
The relatively robust and simple cell culture procedures to
expand CIK cells have enabled this approach of adoptive
cellular immunotherapy to be increasingly studied across
the world. As an immunotherapeutic modality, infusion
of CIK cells is most likely to show eﬃcacy in a relatively
low tumor burden stage or in an adjuvant setting, rather
than in high tumor burden diseases. With the amount of
encouraging experimental and clinical evidence currently
available, randomized clinical trials are justiﬁable and have
to be done under stringent compliance with the CONSORT
principles. This will likely involve a substantial number of
patients in order to demonstrate statistical signiﬁcance for
a modest degree of outcome superiority. Such studies are
urgently needed in order to provide unequivocal evidence
of the clinical usefulness of CIK cells, so as to enable
its integration into cancer treatment protocols to improve
overall cure rate.
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